Citation Impact
Citing Papers
Reactive Oxygen Species in Inflammation and Tissue Injury
2013 Standout
Sexual Dysfunction, Depression, and the Impact of Antidepressants
2009
Cancer treatment and survivorship statistics, 2022
2022 Standout
Tadalafil Therapy for Pulmonary Arterial Hypertension
2009 Standout
Efficacy and Tolerability of Tadalafil for Treatment of Erectile Dysfunction in Men Taking Serotonin Reuptake Inhibitors
2011
Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials
2013 Standout
Current oral treatments for erectile dysfunction
2002
Conversion of Phosphodiesterase-5 (PDE5) Catalytic Site to Higher Affinity by PDE5 Inhibitors
2007
The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin
2005 Standout
Binding of Tritiated Sildenafil, Tadalafil, or Vardenafil to the Phosphodiesterase-5 Catalytic Site Displays Potency, Specificity, Heterogeneity, and cGMP Stimulation
2004
Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline
2010 Standout
Nitric oxide synthases: regulation and function
2011 Standout
Evaluation of the Efficacy and Safety of Once-a-Day Dosing of Tadalafil 5mg and 10mg in the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
2006
Phosphodiesterase-5 Inhibition: the Molecular Biology of Erectile Function and Dysfunction
2005
Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial
2012
Update on Phosphodiesterase (PDE) Isoenzymes as Pharmacologic Targets in Urology: Present and Future
2006
Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents
2005 Standout
The complex interaction between obesity, metabolic syndrome and reproductive axis: A narrative review
2012
Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction
2006
Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use
2006 Standout
Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and management
2010
Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis
2014
Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-Analysis
2010 Standout
Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies
2019 Standout
Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations
2016 Standout
Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension
2004
Efficacy and Safety of Tadalafil Monotherapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Meta-Analysis
2013 Standout
Organic Causes of Erectile Dysfunction in Men Under 40
2013 Standout
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy
2005 Standout
Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice
2007
Testosterone and insulin resistance in the metabolic syndrome and T2DM in men
2013
Evidence for the formation of a novel nitrosothiol from the gaseous mediators nitric oxide and hydrogen sulphide
2006
Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications
2005
Overview of phosphodiesterase 5 inhibition in erectile dysfunction
2003
Sex and gender: modifiers of health, disease, and medicine
2020 Standout
Effect of Testosterone Supplementation on Functional Mobility, Cognition, and Other Parameters in Older Men
2008
cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action
2010 Standout
Low Testosterone in Men with Type 2 Diabetes: Significance and Treatment
2011
Lack of Exercise Is a Major Cause of Chronic Diseases
2012 Standout
PDE5 is converted to an activated state upon cGMP binding to the GAF A domain
2003
Sexual dysfunction in men and women with endocrine disorders
2007
EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction
2013 Standout
Hydrogen sulphide and its therapeutic potential
2007 Standout
Testosterone and glucose metabolism in men: current concepts and controversies
2013
Potency, selectivity, and consequences of nonselectivity of PDE inhibition
2004
Implications of PDE4 structure on inhibitor selectivity across PDE families
2004
From rapalogs to anti-aging formula
2017
Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction
2002
What We Talk About When We Talk About Fat
2014 Standout
Gender differences in glucose homeostasis and diabetes
2017
Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance
2004
The Role of Nitric Oxide in Erectile Dysfunction: Implications for Medical Therapy
2006
Endothelial dysfunction in diabetic erectile dysfunction
2006
Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
2018 Standout
Monotherapy with Tadalafil or Tamsulosin Similarly Improved Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in an International, Randomised, Parallel, Placebo-Controlled Clinical Trial
2012
Inflammation in obesity, diabetes, and related disorders
2022 Standout
Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function
2008
The Thromboxane/Endoperoxide Receptor (TP): The Common Villain
2010
Phosphodiesterase 5 Inhibitors for Erectile Dysfunction
2005
Physiological Implications of Hydrogen Sulfide: A Whiff Exploration That Blossomed
2012 Standout
Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice
2008
EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals
2015 Standout
Diabetic Neuropathies
2005 Standout
Vardenafil, a New Phosphodiesterase Type 5 Inhibitor, in the Treatment of Erectile Dysfunction in Men With Diabetes
2003
Long-Term Safety and Efficacy of Tadalafil 5 mg Dosed Once Daily in Men with Erectile Dysfunction
2008
Increased frequency of anxiety, depression, quality of life and sexual life in young hypogonadotropic hypogonadal males and impacts of testosterone replacement therapy on these conditions
2012
Testosterone and obesity
2015
Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus
2016 Standout
Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
2002
Inhibition of the tonic contraction in the treatment of erectile dysfunction
2003
Cyclic GMP Phosphodiesterases and Regulation of Smooth Muscle Function
2003
The Paradox of Progress: Environmental Disruption of Metabolism and the Diabetes Epidemic
2011
Pharmacology of Penile Erection
2001
Natriuretic Peptides, Their Receptors, and Cyclic Guanosine Monophosphate-Dependent Signaling Functions
2005 Standout
Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline
2017
Testosterone Therapy in Men With Hypogonadism Prevents Progression From Prediabetes to Type 2 Diabetes: Eight-Year Data From a Registry Study
2019
Hormones and Endocrine-Disrupting Chemicals: Low-Dose Effects and Nonmonotonic Dose Responses
2012 Standout
Effect of Testosterone Replacement on Response to Sildenafil Citrate in Men With Erectile Dysfunction
2012
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
2011 Standout
Effects of Intensive Lifestyle Changes on Erectile Dysfunction in Men
2008
Erectile Dysfunction and Correlated Factors in Brazilian Men Aged 18–40 years
2009
Cancer treatment and survivorship statistics, 2019
2019 Standout
Mechanisms of Diabetic Complications
2013 Standout
Ca2+Sensitivity of Smooth Muscle and Nonmuscle Myosin II: Modulated by G Proteins, Kinases, and Myosin Phosphatase
2003 Standout
Biomedical Importance of Indoles
2013 Standout
Therapeutic Potential of Phosphodiesterase 5 Inhibition for Cardiovascular Disease
2003
Prostaglandins and Inflammation
2011 Standout
Anatomy, Physiology, and Pathophysiology of Erectile Dysfunction
2010
Biochemistry and Physiology of Cyclic Nucleotide Phosphodiesterases: Essential Components in Cyclic Nucleotide Signaling
2007 Standout
Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells
2002
Testosterone Supplementation and Sexual Function: A Meta-Analysis Study
2014
Industry sponsorship and research outcome
2017 Standout
Works of Ignacio Moncada being referenced
Diabetes impairs endothelium-dependent relaxation of human penile vascular tissues mediated by NO and EDHF
2003
Current role of penile implants for erectile dysfunction
2004
Core document on erectile dysfunction: key aspects in the care of a patient with erectile dysfunction
2004
An Evaluation of an Alternative Dosing Regimen with Tadalafil, 3 Times/Week, for Men with Erectile Dysfunction: SURE Study in 14 European Countries
2005
Activation and potentiation of the NO/cGMP pathway by NG‐hydroxyl‐L ‐arginine in rabbit corpus cavernosum under normoxic and hypoxic conditions and ageing
2003
Efficacy of Sildenafil Citrate at 12 Hours after Dosing: Re-exploring the Therapeutic Window
2004
Management of end-stage erectile dysfunction and stress urinary incontinence after radical prostatectomy by simultaneous dual implantation using a single trans-scrotal incision: surgical technique and outcomes
2014
Effects of Tadalafil Treatment on Erectile Function Recovery Following Bilateral Nerve-sparing Radical Prostatectomy: A Randomised Placebo-controlled Study (REACTT)
2013
Long-Term Safety and Tolerability of Tadalafil in the Treatment of Erectile Dysfunction
2003
Enhanced Thromboxane Receptor-Mediated Responses and Impaired Endothelium-Dependent Relaxation in Human Corpus Cavernosum from Diabetic Impotent Men: Role of Protein Kinase C Activity
2006
Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events
2011
Effect of lamotrigine on sexual function in patients with epilepsy
2006
Testosterone and men's quality of life
2006
The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil
2001
Rationale for the Combination of PGE1 andS-Nitroso-glutathione to Induce Relaxation of Human Penile Smooth Muscle
2000
Fisiología de la erección
2010
Evaluation of the Psychometric Properties of the Life Satisfaction Checklist as a Screening Tool for Erectile Dysfunction
2007
Hypogonadal Men Nonresponders to the PDE5 Inhibitor Tadalafil Benefit from Normalization of Testosterone Levels with a 1% Hydroalcoholic Testosterone Gel in the Treatment of Erectile Dysfunction (TADTEST Study)
2010
Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study)
2011